|
Clinical symptom |
SLE |
RA |
SSc |
PM |
MCTD | |
|
Pleuritis or pericarditis |
++++ |
+ |
+ |
– |
+++ | |
|
Arthritis with joint destruction |
± |
++++ |
+ |
± |
+ | |
|
Raynaud phenomenon |
++ |
– |
++++ |
+ |
++++ | |
|
Myositis |
+ |
+ |
+ |
++++ |
+++ | |
|
Sclerodactyly |
± |
– |
++++ |
– |
++ | |
|
Skin thickening |
– |
– |
+++ |
– |
– | |
|
Interstitial lung disease |
+ |
+ |
+++ |
++ |
+ | |
|
Pulmonary hypertension |
+ |
± |
++ |
+ |
+++ | |
|
Butterfly rash |
++++ |
– |
– |
– |
++ | |
|
Oral ulcers |
+++ |
– |
– |
– |
++ | |
|
Seizures or psychosis |
+++ |
– |
– |
– |
– | |
|
Nerve V neuropathy |
+ |
– |
++ |
– |
+++ | |
|
Peripheral polyneuropathy |
++ |
++ |
± |
– |
++ | |
|
Transverse myelitis |
+++ |
+ |
– |
– |
++ | |
|
Aseptic meningitis |
+++ |
+ |
– |
– |
+++ | |
|
Glomerulonephritis |
||||||
|
Proliferative |
++++ |
– |
– |
– |
+ | |
|
Membranous |
+++ |
– |
– |
– |
++ | |
|
Renovascular hypertension |
+ |
– |
++++ |
– |
+++ | |
|
Cutaneous (leukocytoclastic vasculitis on skin biopsy) or systemic vasculitis, including renal, neurologic, and pulmonary manifestations) |
++ |
++ |
+ |
+ |
+ | |
|
Noninflammatory vasculopathy |
– |
– |
++++ |
– |
+++ | |
|
Impaired esophageal motility |
± |
± |
++++ |
++ |
+++ | |
|
Anti-RNP |
++ |
– |
+ |
+ |
++++ | |
|
Anti-Sm |
+++ |
– |
– |
– |
– | |
|
Anti-dsDNA |
++++ |
– |
– |
– |
– | |
|
Anti-Scl-70, ACAs, anti-RNA polymerase III |
– |
– |
+++ |
– |
– | |
|
↓ levels of complement components |
+++ |
– |
– |
– |
+/–
| |
|
Rheumatoid factor |
++ |
+++ |
+ |
+ |
++ | |
|
The number of pluses denotes the frequency. | ||||||
|
↓, decreased; ACA, anticentromere antibody; dsDNA, double-stranded DNA; MCTD, mixed connective tissue disease; PM, polymyositis; RA, rheumatoid arthritis; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. | ||||||